Mechanisms of Neural Cell Death: Implications for Development of Neuroprotective Treatment Strategies

被引:85
作者
Yakovlev A.G. [1 ]
Faden A.I. [1 ]
机构
[1] Department of Neuroscience, Georgetown University Medical Center, Washington
来源
NeuroRX | 2004年 / 1卷 / 1期
基金
美国国家卫生研究院;
关键词
AIF; Apoptosis; calpain; caspase; necrosis;
D O I
10.1602/neurorx.1.1.5
中图分类号
学科分类号
摘要
It has been increasingly recognized that cell death phenotypes and their molecular mechanisms are highly diverse. Necrosis is no longer considered a single entity, passively mediated by energy failure. Moreover, caspase-dependent apoptosis is not the only pathway involved in programmed cell death or even the only apoptotic mechanism. Recent experimental work emphasizes the diverse and interrelated nature of cell death mechanisms. Thus, there are both caspase-dependent and caspase-independent forms of apoptosis, which may differ morphologically as well as mechanistically. There are also necrotic-like phenotypes that require de novo protein synthesis and are, therefore, forms of programmed cell death. In addition, forms of cell death showing certain morphological features of both necrosis and apoptosis have been identified, leading to the term aponecrosis. Considerable experimental evidence also shows that modulation of one form of cell death may lead to another. Together, these observations underscore the need to substantially revise our conceptions about neuroprotection strategies. Use of multiple treatments that target different cell death cascades, or single agents that moderate multiple cell death pathways, is likely to lead to more effective neuroprotection for clinical disorders. © 2004 The American Society for Experimental NeuroTherapeutics, Inc.
引用
收藏
页码:5 / 16
页数:11
相关论文
共 131 条
[1]  
Eldadah B., Faden A., Caspase pathways, neuronal apoptosis, and CNS injury, J Neurotrauma, 17, pp. 811-829, (2000)
[2]  
Snider B., Gottron F., Choi D., Apoptosis and necrosis in cerebrovascular disease, Ann NY Acad Sci, 893, pp. 243-253, (1999)
[3]  
Graeber M., Moran L., Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts, Brain Pathol, 12, pp. 385-390, (2002)
[4]  
Honig L., Rosenberg R., Apoptosis and neurologic disease, Am J Med, 108, pp. 317-330, (2000)
[5]  
Panter S., Faden A., Biochemical changes and secondary injury from stroke and trauma, Principles and practice of restorative neurology, pp. 32-52, (1992)
[6]  
McIntosh T., Neurochemical sequelae of traumatic brain injury: therapeutic implications, Cerebrovasc Brain Metab Rev, 6, pp. 109-162, (1994)
[7]  
Pohl D., Bittigau P., Ishimaru M., Stadthaus D., Hubner C., Olney J., Et al., N-methyl-d-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain, Proc Natl Acad Sci USA, 96, pp. 2508-2513, (1999)
[8]  
Faden A., Pharmacological treatment of central nervous system trauma, Pharmacol Toxicol, 78, pp. 12-17, (1996)
[9]  
Pitts L., Ross A., Chase G., Faden A., Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries, J Neurotrauma, 12, pp. 235-243, (1995)
[10]  
Bracken M., Holford T., Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2, J Neurosurg, 79, pp. 500-507, (1993)